|
CN112266411A
|
|
Novel coronavirus vaccine and application thereof
|
|
CN111285930A
|
|
Nucleic acid molecule for coding parathyroid hormone protein or fragment thereof
|
|
CN109535243A
|
|
Human hepatocyte growth factor mutant and its application
|
|
CN109865127A
|
|
Purposes of the modified extrasin beta 4 in terms for the treatment of diabete peripheral herve pathology
|
|
CN110215513A
|
|
Purposes of the modified extrasin beta 4 in terms of therapeutic radiation enteritis
|
|
CN108853483A
|
|
Modified extrasin beta 4 is in the purposes for treating cerebral ischemia re-pouring injured aspect
|
|
CN109055389A
|
|
The recombinant plasmid of carrier's glucagon-like peptide 1 (7-36) gene
|
|
CN108498788A
|
|
The purposes of modified extrasin beta 4
|
|
CN108611367A
|
|
The gene therapy recombinant vector that one kind is mediated by plasmid vector
|
|
CN106692949A
|
|
Medicine for treating eye diseases and composition of medicine
|
|
CN106282227A
|
|
A kind of fermentation process in high density of recombinant human hepatocyte growth factor gymnoplasm grain
|
|
CN105891399A
|
|
Method for detecting thymosin beta 4 content based on high performance liquid chromatograph
|
|
CN105886581A
|
|
High-density fermentation method of recombinant human thymalfasin
|
|
CN105017410A
|
|
Zone B partially-deleted type recombinant human blood coagulation factor VIII
|
|
CN101433713A
|
|
GnRH-PE mutant fusion protein and uses thereof
|
|
WO2007009359A1
|
|
Thymosin beta 4 derivatives and use thereof
|
